Bioxcel Drug Patent Portfolio

Bioxcel owns 1 orange book drug protected by 11 US patents Given below is the list of Bioxcel's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11806334 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
Active
US11998528 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
Active
US12090140 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
Active
US11890272 Non-sedating dexmedetomidine treatment regimens 17 Jul, 2040
Active
US11998529 Non-sedating dexmedetomidine treatment regimens 17 Jul, 2040
Active
US10792246 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
Active
US11478422 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
Active
US11497711 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
Active
US11517524 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
Active
US11786508 Use of sublingual dexmedetomidine for the treatment of agitation 29 Dec, 2037
Active
US11839604 Use of sublingual dexmedetomidine for the treatment of agitation 29 Dec, 2037
Active


Given below is the list of recent legal activities going on the following drug patents of Bioxcel.

Activity Date Patent Number
Patent litigations
Email Notification 24 Apr, 2024 US11890272
Mail Patent eCofC Notification 23 Apr, 2024 US10792246
Email Notification 23 Apr, 2024 US11890272
Recordation of Patent eCertificate of Correction 23 Apr, 2024 US11890272
Mail Patent eCofC Notification 23 Apr, 2024 US11890272
Recordation of Patent eCertificate of Correction 23 Apr, 2024 US10792246
Patent eCofC Notification 23 Apr, 2024 US10792246
Email Notification 23 Apr, 2024 US10792246
Patent eCofC Notification 23 Apr, 2024 US11890272
Post Issue Communication - Certificate of Correction 04 Apr, 2024 US11890272
Payment of Maintenance Fee, 4th Yr, Small Entity 20 Mar, 2024 US10792246
Patent eGrant Notification 06 Feb, 2024 US11890272
Email Notification 06 Feb, 2024 US11890272
Mail Patent eGrant Notification 06 Feb, 2024 US11890272
Recordation of Patent eGrant 06 Feb, 2024 US11890272


Bioxcel's Family Patents

Bioxcel drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 47.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Bioxcel Drug List

Given below is the complete list of Bioxcel's drugs and the patents protecting them.


1. Igalmi

Igalmi is protected by 11 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11806334 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
(18 years from now)
Active
US11998528 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
(18 years from now)
Active
US12090140 Non-sedating dexmedetomidine treatment regimens 12 Jan, 2043
(18 years from now)
Active
US11890272 Non-sedating dexmedetomidine treatment regimens 17 Jul, 2040
(15 years from now)
Active
US11998529 Non-sedating dexmedetomidine treatment regimens 17 Jul, 2040
(15 years from now)
Active
US10792246 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
(14 years from now)
Active
US11478422 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
(14 years from now)
Active
US11497711 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
(14 years from now)
Active
US11517524 Film formulations containing dexmedetomidine and methods of producing them 26 Jun, 2039
(14 years from now)
Active
US11786508 Use of sublingual dexmedetomidine for the treatment of agitation 29 Dec, 2037
(13 years from now)
Active
US11839604 Use of sublingual dexmedetomidine for the treatment of agitation 29 Dec, 2037
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Igalmi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List